IP Watchdog

JANUARY 9, 2024

Patent and Trademark Office (USPTO) published guidelines for examiners today on the topic of enablement in light of the Supreme Court’s May 2023 decision in Amgen v.

Publishing 114

Publishing Trademark Patent Patent Prosecution 114

The IPKat

OCTOBER 9, 2023

This 3-day conference promises to offer 200+ private practice and in-house participants a forum of practical discussions surrounding the leading patent litigation topics in Europe, with a compare-and-contrast method with jurisdictions further afield. A UPC Litigation Forum will take place on 22 January too.

Litigation 62

Litigation Patent Editing IP 62

Patently-O

OCTOBER 4, 2023

IP Timely Topics CLE – November 14, 2023 – Washington State Bar Association I’m delighted to be presenting again this year at the Washington State Bar Association’s IP section meeting. My presentation will focus on the implications of the Amgen vs. Sanofi decision for both biotech and “regular” tech.

Intellectual Property Law 49

Intellectual Property Law Intellectual Property IP Trademark Law 49

Patently-O

NOVEMBER 6, 2022

Sanofi , that rely on a lack of enablement to hold that functionally defined genus claims are invalid. Sanofi , that rely on a lack of enablement to hold that functionally defined genus claims are invalid. The other case is a Abitron Austria GmbH v. Hetronic International , a trademark dispute involving extraterritoriality issues.

Invention 64

Invention Art Patent Law Intellectual Property 64

Patently-O

SEPTEMBER 26, 2022

Topics: Enablement / Written Description (All three are biotech / pharma): 3 Cases; Infringement (FDA Labeling): 1 Case; Anticipation (On Sale Bar): 1 Case; Double Patenting (Still the law?) Sanofi as well as with the likely upcoming petition in Novartis Pharm. Sanofi, No. Accord Healthcare, Inc., 4th 1013 (Fed.

Patent Law 126

Patent Law Law Patent Invention 126

The IPKat

DECEMBER 22, 2023

G2/21 and the mysteries of plausibility The topic that this Kat has spent the most electronic ink on this year is undoubtedly G 2/21. After a flurry of decisions at the start of the year , the Boards of Appeal have gone rather silent on the topic of ViCo oral proceedings. This is one to watch for 2024. EPO maintains ST.26

Invention 110

Invention Inventor Patent Law 110

Patently-O

FEBRUARY 24, 2022

The Kessler Doctrine : If you want to really dig into this case, please read my article on the topic that I wrote for an Akron Law review IP symposium issue. Sanofi has the potential of being a huge case in terms of how it impacts the future of biotech innovation. 2022)(forthcoming). .” ” Full Scope Enablement : Amgen v.

Patent Law 95

Patent Law Law Patent Litigation 95